Back to Top

Ask about this
Protocol

Protocol
Open Access
  • © Akihiro Kume
  • , et al.
  • 2022

Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan

  • Akihiro Kume 1
  • Eriko Uchida 2
  • Hiroyuki Mizuguchi 3
  • Kazushige Maki 4
  • Keiya Ozawa 1
  • Kenzaburo Tani 5
  • Kohnosuke Mitani 6
  • Masafumi Onodera 7
  • Satoru Takahashi 8
  • Takashi Okada 5
  • Takashi Shimada 9
  • Teruhide Yamaguchi 10
  • Tomoji Mashimo 5
  • Yasutomo Nasu 11
  • 1 - Jichi Medical University
  • 2 - National Institute of Health Sciences
  • 3 - Osaka University
  • 4 - Pharmaceuticals and Medical Devices Agency
  • 5 - The University of Tokyo
  • 6 - Saitama Medical University
  • 7 - National Center for Child Health and Development
  • 8 - University of Tsukuba
  • 9 - Nippon Medical School
  • 10 - Kanazawa Institute of Technology - Ishikawa Japan
  • 11 - Okayama University Graduate School of Medicine - Dentistry and Pharmaceutical Sciences

Abstract

The development of genome-editing technology could lead to breakthrough gene therapy. Genome editing has made it possible to easily knock out or modify a target gene, while current gene therapy using a virus vector or plasmid hampering modification with respect to gene replacement therapies. Clinical development using these genome-editing tools is progressing rapidly. However, it is also becoming clear that there is a possibility of unintended gene sequence modification or deletion, or the insertion of undesired genes, or the selection of cells with abnormalities in the cancer suppressor gene p53; these unwanted actions are not possible with current gene therapy. The Science Board of the Pharmaceuticals and Medical Devices Agency of Japan has compiled a report on the expected aspects of such genome-editing technology and the risks associated with it. This article summarizes the history of that discussion and compares the key concepts with information provided by other regulatory authorities.


Comments

Be the first to comment on this protocol.

Submit a Comment

First Name *

Last Name *

Email *

Comments *

By submitting this form, you agree to the Genetic Engineering & Biotechnology News (GEN) privacy policy.

Premier Sponsor
Horizon Discovery